Jan 21, 2025 · Titusville, New Jersey, January 21, 2025 – Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO ® (esketamine) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate response to ...

5 days ago · Johnson & Johnson. Rationale for Use of SPRAVATO in conjunction with oral antidepressant during phase 3 studies. Johnson & Johnson. Spravato (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression.

Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression

Jan 21, 2025 · References: Spravato ® (esketamine) approved in the US as the first and only monotherapy for adults with treatment-resistant depression. News release. Johnson & Johnson. January 21, 2025. https ...

Jan 22, 2025 · Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and ...

6 days ago · A study by Johnson & Johnson, the company that makes Spravato, showed that 22.5% of people using esketamine nasal spray achieved remission from major depression in four weeks. Just 7.6% of people ...

Jan 21, 2025 · The FDA has approved esketamine (Spravato) for the treatment of major depressive disorder (MDD) in adult patients who have had inadequate response to at least 2 oral antidepressants, Johnson and Johnson announced in a release. 1 The decision makes Spravato the first and only monotherapy approved for adults living with the condition.

Jan 22, 2025 · Major depressive disorder (MDD) is characterised by characterised by depression and inability to feel pleasure. Credit: Justin Paget via Getty Images. Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major ...

Jan 22, 2025 · Behavioral and Biomedical Sciences Building (BBSB) 1941 East Road Houston, Texas 77054 map. Phone: 713-486-2500 Email: [email protected]

6 days ago · Mattingly has been involved with recent research and clinical trials regarding Spravato (esketamine) — a prescription nasal spray made by Johnson & Johnson (J&J) used to treat depression that ...